Evidence map›Paper›PMID 31018249›Full record

ArticleInternational journal of cancer2019

Fisetin and 5-fluorouracil: Effective combination for PIK3CA-mutant colorectal cancer.

Naghma Khan, Farah Jajeh, Emily L Eberhardt, Devon D Miller, Dawn M Albrecht, Rachel Van Doorn, Melissa D Hruby, Morgan E Maresh, Linda Clipson, Hasan Mukhtar and 1 more

Open access · bronzeAbstract read
In one paragraph

Article in International journal of cancer, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed, 1 pooled it
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 1 synthesis or guideline pooled it, 40 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Review
  12. Review
  13. Article
  14. Raw Lacquer Extract from Toxicodendron vernicifluum in Combination with ONC201 Enhances the Inhibitory Effects on Colorectal Cancer Cell Activity.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2023
    Article
  15. Review
  16. Article
  17. Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Naghma KhanDepartment of Dermatology, University of Wisconsin-Madison, Madison, WI.ORCID 0000-0001-8575-0545
Farah JajehDepartment of Dermatology, University of Wisconsin-Madison, Madison, WI.
Emily L EberhardtDivision of Gastroenterology and Hepatology, Department of Medicine, University of Wisconsin-Madison, Madison, WI.
Devon D MillerDivision of Gastroenterology and Hepatology, Department of Medicine, University of Wisconsin-Madison, Madison, WI.
Dawn M AlbrechtDivision of Gastroenterology and Hepatology, Department of Medicine, University of Wisconsin-Madison, Madison, WI.
Rachel Van DoornDivision of Gastroenterology and Hepatology, Department of Medicine, University of Wisconsin-Madison, Madison, WI.
Melissa D HrubyDepartment of Dermatology, University of Wisconsin-Madison, Madison, WI.
Morgan E MareshDivision of Gastroenterology and Hepatology, Department of Medicine, University of Wisconsin-Madison, Madison, WI.
Linda ClipsonDepartment of Oncology, McArdle Laboratory for Cancer Research, University of Wisconsin-Madison, Madison, WI.
Hasan MukhtarDepartment of Dermatology, University of Wisconsin-Madison, Madison, WI.
Richard B HalbergUniversity of Wisconsin Carbone Cancer Center, Madison, WI.
University of Wisconsin–Madison · US

Funding

UW COMPREHENSIVE CANCER CENTER SUPPORTP30CA014520 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI AMY TRENTHAM-DIETZ · 1985 to 2026
$142.6M
NCI NIH HHS P30 CA014520
6 · The paper itself

Abstract

The normal colon epithelium is transformed into its neoplastic counterpart through a series of genetic alterations in driver genes including activating mutations in PIK3CA. Treatment often involves surgery followed by 5-fluorouracil (5-FU) based therapy, which has limited efficiency and serious side effects. We sought to determine whether fisetin, a dietary flavonoid, alone or in combination with 5-FU affected tumorigenesis in the mammalian intestine. We first determined the effect of fisetin, 5-FU or their combination on PIK3CA-mutant and PIK3CA wild-type colon cancer cells by assessing cell viability, colony formation, apoptosis and effects on PI3K/AKT/mTOR signaling. Treatment of PIK3CA-mutant cells with fisetin and 5-FU reduced the expression of PI3K, phosphorylation of AKT, mTOR, its target proteins, constituents of mTOR signaling complex and this treatment increased the phosphorylation of AMPKα. We then determined whether fisetin and 5-FU together or singly affected tumorigenesis in Apc

Indexed as

MutationAnimalsAntineoplastic Combined Chemotherapy ProtocolsCell Line, TumorCell ProliferationCell SurvivalClass I Phosphatidylinositol 3-KinasesColorectal NeoplasmsDrug SynergismFlavonoidsFlavonolsFluorouracilHCT116 CellsHT29 CellsHumansMiceClass I Phosphatidylinositol 3-KinasesfisetinFlavonoidsFlavonolsFluorouracilPIK3CA protein, human5-fluorouracilcolorectal cancerPI3K/AKT/mTOR signalingPIK3CA

Identifiers

PMID31018249
PMCPMC7465634
OpenAlexW2941057324

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.